Successful treatment of refractory red cell aplasia after allogeneic hematopoietic cell transplantation with daratumumab
- 6 November 2019
- journal article
- case report
- Published by Wiley in European Journal of Haematology
- Vol. 104 (2) , 145-147
Abstract
Pure red cell aplasia (PRCA) is an uncommon complication secondary to ABO mismatched allogeneic stem‐cell transplantation (allo‐HSCT). The best approach for PRCA after allo‐HSCT remains unclear. We aim to report a single case with refractory PRCA post‐ABO mismatched allo‐HSCT resolved with daratumumab. A 34‐year‐old male diagnosed with aplastic anemia in March 2014 received a peripheral blood reduced‐intensity allo‐HSCT from an HLA‐matched related donor in July 2016. Donor and recipient blood groups were AB positive and 0 positive, respectively, indicating a major ABO incompatibility. The patient was diagnosed with PRCA 2 months after allo‐HSCT. After failing multiple standard lines of treatment, compassionate treatment with daratumumab was requested. After receiving six doses of daratumumab, the patient had a marked reticulocyte response and consecutively become transfusion independent. In conclusion, Daratumumab is a human IgG1κ monoclonal antibody targeting CD38 and is used to treat multiple myeloma. The use of anti‐CD38 therapy with daratumumab to target residual host plasma cells is safe and effective, and it can be considered in refractory recipients with PRCA after allo‐HSCT secondary to ABO incompatibility.Keywords
This publication has 5 references indexed in Scilit:
- Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumabAmerican Journal of Hematology, 2019
- Daratumumab for Delayed Red-Cell Engraftment after Allogeneic TransplantationNew England Journal of Medicine, 2018
- Successful treatment of pure red cell aplasia because of ABO major mismatched stem cell transplantJournal of Clinical Apheresis, 2017
- Subcutaneous bortezomib is highly effective for pure red cell aplasia after ABO‐incompatible haematopoietic stem cell transplantationTransfusion Medicine, 2014
- Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantationBlood, 2001